TY - JOUR AU - Palella, F. J. AU - Delaney, K. M. AU - Moorman, A. C. AU - Loveless, M. O. AU - Fuhrer, J. AU - Satten, G. A. AU - Aschman, D. J. AU - Holmberg, S. D. PY - 1998 DA - 1998// TI - Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection JO - N Engl J Med VL - 338 UR - https://doi.org/10.1056/NEJM199803263381301 DO - 10.1056/NEJM199803263381301 ID - Palella1998 ER - TY - JOUR AU - Hogg, R. S. AU - Yip, B. AU - Kully, C. AU - Craib, K. J. AU - O'Shaughnessy, M. V. AU - Schechter, M. T. AU - Montaner, J. S. PY - 1999 DA - 1999// TI - Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens JO - CMAJ VL - 160 ID - Hogg1999 ER - TY - STD TI - Jordan J, Carranza Rosenzweig J, Pathak D, Pilon T: Perceived influence of regimen characteristics on adherence. 5th International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom. Abstract/Poster 121: October 22–26, 2000 ID - ref3 ER - TY - JOUR AU - Currier, J. S. PY - 2002 DA - 2002// TI - Cardiovascular risk associated with HIV therapy JO - J Acquir Immune Defic Syndr VL - 31 UR - https://doi.org/10.1097/00126334-200209011-00004 DO - 10.1097/00126334-200209011-00004 ID - Currier2002 ER - TY - JOUR AU - Periard, D. AU - Telenti, A. AU - Sudre, P. AU - Cheseaux, J. J. AU - Halfon, P. AU - Reymond, M. J. AU - Marcovina, S. M. AU - Glauser, M. P. AU - Nicod, P. AU - Darioli, R. AU - Mooser, V. PY - 1999 DA - 1999// TI - Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study JO - Circulation VL - 100 UR - https://doi.org/10.1161/01.CIR.100.7.700 DO - 10.1161/01.CIR.100.7.700 ID - Periard1999 ER - TY - STD TI - Piliero PJ, Cahn P, Pantaleo G, Gatell J, Squires K, Percival L, Sanne I, Wood R, Phanuphak P, Shelton S, Lazzarin A, Thiry A, Kelleher T, Giordano M, Schnittman SM: Atazanavir: a once-daily protease inhibitor with a superior lipid profile – results of clinical trials at week 48. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. Abstract/poster 706T: February 24–28, 2002 ID - ref6 ER - TY - JOUR AU - Rodriguez-French, A. AU - Boghossian, J. AU - Gray, G. E. AU - Nadler, J. P. AU - Quinones, A. R. AU - Sepulveda, G. E. AU - Millard, J. M. AU - Wannamaker, P. G. PY - 2004 DA - 2004// TI - The NEAT study: a 48-week study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-infected patients JO - J Acquir Immune Defic Syndr VL - 35 UR - https://doi.org/10.1097/00126334-200401010-00003 DO - 10.1097/00126334-200401010-00003 ID - Rodriguez-French2004 ER - TY - STD TI - Horban A, Staszewski S, Walmsley S, Pierone G, Sexton A, Stark T: Favourable increases in high-density lipoprotein cholesterol (HDL-C) concentrations in chronic HIV-infected therapy-naïve subjects receiving 908/r in the SOLO study (APV30002). 9th European AIDS Conference. Warsaw, Poland. Abstract/slide presentation F 8/3: October 25–29, 2003 ID - ref8 ER - TY - JOUR AU - Grunfeld, C. AU - Pang, M. AU - Doerrler, W. AU - Shigenaga, J. K. AU - Jensen, P. AU - Feingold, K. R. PY - 1992 DA - 1992// TI - Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome JO - J Clin Endocrinol Metab VL - 74 ID - Grunfeld1992 ER - TY - JOUR AU - Petit, J. M. AU - Duong, M. AU - Duvillard, L. AU - Florentin, E. AU - Portier, H. AU - Lizard, G. AU - Brun, J. M. AU - Gambert, P. AU - Verges, B. PY - 2002 DA - 2002// TI - LDL-receptors expression in HIV-infected patients: relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy JO - Eur J Clin Invest VL - 32 UR - https://doi.org/10.1046/j.1365-2362.2002.00989.x DO - 10.1046/j.1365-2362.2002.00989.x ID - Petit2002 ER - TY - JOUR AU - Riddle, T. M. AU - Kuhel, D. G. AU - Woolett, L. A. AU - Fichtenbaum, C. AU - Hui, D. Y. PY - 2001 DA - 2001// TI - HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus JO - J Biol Chem VL - 276 UR - https://doi.org/10.1074/jbc.M104557200 DO - 10.1074/jbc.M104557200 ID - Riddle2001 ER - TY - JOUR AU - Sekhar, R. V. AU - Jahoor, F. AU - White, A. C. AU - Pownall, H. J. AU - Visnegarwala, F. AU - Rodriguez-Barradas, M. C. AU - Sharma, M. AU - Reeds, P. J. AU - Balasubramanyam, A. PY - 2002 DA - 2002// TI - Metabolic basis of HIV-lipodystrophy syndrome JO - Am J Physiol-Endocrinol Metab VL - 283 UR - https://doi.org/10.1152/ajpendo.00058.2002 DO - 10.1152/ajpendo.00058.2002 ID - Sekhar2002 ER - TY - JOUR AU - Klein, D. AU - Hurley, L. B. AU - Quesenberry, C. P. AU - Sidney, S. PY - 2002 DA - 2002// TI - Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection JO - J Acquir Immune Defic Syndr VL - 30 UR - https://doi.org/10.1097/00126334-200208150-00002 DO - 10.1097/00126334-200208150-00002 ID - Klein2002 ER - TY - STD TI - Holmberg S, Moorman A, Tong T, Ward D, Wood K, Greenberg AE, Janssen RS, for the HIV Outpatient Study (HOPS) Investigators: Protease inhibitor use and adverse cardiovascular outcomes in ambulatory HIV patients. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. Abstract 698T: February 24–28, 2002 ID - ref14 ER - TY - JOUR AU - Bozzette, S. A. AU - Ake, C. F. AU - Tam, H. K. AU - Chang, S. W. AU - Louis, T. A. PY - 2003 DA - 2003// TI - Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection JO - New Engl J Med VL - 348 UR - https://doi.org/10.1056/NEJMoa022048 DO - 10.1056/NEJMoa022048 ID - Bozzette2003 ER - TY - JOUR AU - Hervey, P. S. AU - Perry, C. M. PY - 2000 DA - 2000// TI - Abacavir – a review of its clinical potential in patients with HIV infection JO - Drugs VL - 60 UR - https://doi.org/10.2165/00003495-200060020-00015 DO - 10.2165/00003495-200060020-00015 ID - Hervey2000 ER - TY - JOUR AU - Murphy, R. L. AU - Smith, W. J. PY - 2002 DA - 2002// TI - Switch studies: a review JO - HIV Med VL - 3 UR - https://doi.org/10.1046/j.1468-1293.2002.00102.x DO - 10.1046/j.1468-1293.2002.00102.x ID - Murphy2002 ER - TY - JOUR AU - Vibhagool, A. AU - Cahn, P. AU - Schlechter, M. AU - Smaill, F. AU - Soto-Ramirez, L. AU - Carosi, G. AU - Montroni, M. AU - Pharo, C. E. AU - Jordan, J. C. AU - Thomas, N. E. AU - Pearce, G. PY - 2004 DA - 2004// TI - Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open label, equivalence trial (CNA3014) JO - Curr Med Res Opin VL - 20 UR - https://doi.org/10.1185/030079904125004006 DO - 10.1185/030079904125004006 ID - Vibhagool2004 ER - TY - JOUR AU - Matheron, S. AU - Descamps, D. AU - Boué, F. AU - Livrozet, J. -. M. AU - Lafeuillade, A. AU - Aquilina, C. AU - Troisvallets, D. AU - Goetschel, A. AU - Brun-Vezinet, F. AU - Mamet, J. -. P. AU - Thiaux, C. PY - 2003 DA - 2003// TI - Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial JO - Antivir Ther VL - 8 ID - Matheron2003 ER - TY - STD TI - Kumar P, Rodriguez-French A, Thompson M, Tashima K, Wannamaker P, Williams V, Pappa K: Prospective study of hyperlipidemia in ART-naïve subjects taking Trizivir (TZV), Combivir (COM)/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France. Abstract/Poster 709: July 13–16, 2003 ID - ref20 ER - TY - JOUR AU - Staszewski, S. AU - Keiser, P. AU - Montaner, J. AU - Raffi, F. AU - Gathe, J. AU - Brotas, V. AU - Hicks, C. AU - Hammer, S. M. AU - Cooper, D. AU - Johnson, M. AU - Tortell, S. AU - Cutrell, A. AU - Thorborn, D. AU - Isaacs, R. AU - Hetherington, S. AU - Steel, H. AU - Spreen, W. PY - 2001 DA - 2001// TI - Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-infected adults: a randomized equivalence trial JO - JAMA VL - 285 UR - https://doi.org/10.1001/jama.285.9.1155 DO - 10.1001/jama.285.9.1155 ID - Staszewski2001 ER - TY - JOUR AU - Friedewald, W. T. AU - Levy, R. I. AU - Fredrickson, D. S. PY - 1972 DA - 1972// TI - Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultra centrifuge JO - Clin Chem VL - 18 ID - Friedewald1972 ER - TY - JOUR AU - Nauck, M. AU - Warnick, G. R. AU - Rifai, N. PY - 2002 DA - 2002// TI - Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation JO - Clin Chem VL - 48 ID - Nauck2002 ER - TY - JOUR AU - Hetherington, S. AU - McGuirk, S. AU - Powell, G. AU - Cutrell, A. AU - Naderer, O. AU - Spreen, B. PY - 2001 DA - 2001// TI - Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir JO - Clin Ther VL - 23 UR - https://doi.org/10.1016/S0149-2918(01)80132-6 DO - 10.1016/S0149-2918(01)80132-6 ID - Hetherington2001 ER - TY - JOUR AU - Hewitt, R. G. PY - 2002 DA - 2002// TI - Abacavir hypersensitivity reaction JO - Clin Infect Dis VL - 34 UR - https://doi.org/10.1086/339751 DO - 10.1086/339751 ID - Hewitt2002 ER - TY - STD TI - Childress JK, Jhingran P, Scott-Lennox J, Tolson J: Development and initial evaluation of the Patient Medication Adherence Questionnaire (PMAQ). 6th European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, Germany. Abstract/poster N-23: October 11–15, 1997 ID - ref26 ER - TY - CHAP AU - Ware, J. E. AU - Snow, K. K. AU - Kosinski, M. AU - Gandek, B. PY - 1993 DA - 1993// BT - SF-36 Health Survey manual and interpretation guide PB - Nimrod Press CY - Boston, Mass ID - Ware1993 ER - TY - JOUR AU - Katlama, C. AU - Fenske, S. AU - Gazzard, B. AU - Lazzarin, A. AU - Clumeck, N. AU - Mallolas, J. AU - Lafeuillade, A. AU - Mamet, J. -. P. AU - Beauvais, L. PY - 2003 DA - 2003// TI - TRIZAL study: switching from successful HAART to Trizivir™ (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results JO - HIV Med VL - 4 UR - https://doi.org/10.1046/j.1468-1293.2003.00139.x DO - 10.1046/j.1468-1293.2003.00139.x ID - Katlama2003 ER - TY - JOUR AU - Clumeck, N. AU - Goebel, F. AU - Rozenbaum, W. AU - Gerstoft, J. AU - Staszewski, S. AU - Montaner, J. AU - Johnson, M. AU - Gazzard, B. AU - Stone, C. AU - Athisegaran, R. AU - Moore, S. PY - 2001 DA - 2001// TI - Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA JO - AIDS VL - 15 UR - https://doi.org/10.1097/00002030-200108170-00009 DO - 10.1097/00002030-200108170-00009 ID - Clumeck2001 ER - TY - JOUR AU - Opravil, M. AU - Hirschel, B. AU - Lazzarin, A. AU - Furrer, H. AU - Chave, J. -. P. AU - Yerly, S. AU - Bisset, L. R. AU - Fischer, M. AU - Vernazza, P. AU - Bernasconi, E. AU - Battegay, M. AU - Ledergerber, B. AU - Günthard, H. AU - Howe, C. AU - Weber, R. AU - Perrin, L. PY - 2002 DA - 2002// TI - A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection JO - J Infect Dis VL - 185 UR - https://doi.org/10.1086/340312 DO - 10.1086/340312 ID - Opravil2002 ER - TY - JOUR AU - Moyle, G. J. AU - Baldwin, C. AU - Langroudi, B. AU - Mandalia, S. AU - Gazzard, B. G. PY - 2003 DA - 2003// TI - A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy JO - J Acquir Immune Defic Syndr VL - 33 UR - https://doi.org/10.1097/00126334-200305010-00004 DO - 10.1097/00126334-200305010-00004 ID - Moyle2003 ER - TY - JOUR AU - Martínez, E. AU - Arnaiz, J. A. AU - Podzamczer, D. AU - Dalmau, D. AU - Ribera, E. AU - Domingo, P. AU - Knobel, H. AU - Riera, M. AU - Pedrol, E. AU - Force, L. AU - Llibre, J. M. AU - Segura, F. AU - Richart, C. AU - Cortés, C. AU - Javaloyas, M. AU - Aranda, M. AU - Cruceta, A. AU - de Lazzari, E. AU - Gatell, J. M. PY - 2003 DA - 2003// TI - Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection JO - N Engl J Med VL - 349 UR - https://doi.org/10.1056/NEJMoa021589 DO - 10.1056/NEJMoa021589 ID - Martínez2003 ER - TY - STD TI - Pulvirenti J, Goodwin D, Slater L, Rodriguez A, Fleming J, Williams V, Kauf T, Hernandez J: Simplification of protease inhibitor (PI)-containing HAART regimens with abacavir (ABC) maintains viral suppression and favorable adherence in HIV-1 infected adults (COL30305). 39th Annual Meeting of the Infectious Diseases Society of America. San Francisco, California. Abstract/poster 689: October 25–28, 2001 ID - ref33 ER - TY - CHAP PY - 2001 DA - 2001// TI - Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) BT - National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. NIH Publication No. 01-3670 ID - ref34 ER - TY - STD TI - Markowitz M, Simon V, Vasan S, Louie M, Hurley A, Rowe L, Hogan C: 48-Week results of an atazanavir-based QD regimen in patients switching from BID PI-based HAART. 2nd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment. Paris, France. Abstract/poster 543: July 13–16, 2003 ID - ref35 ER - TY - STD TI - Bonnet E, Lepec R, Bluteau M, Herve R, Bernard J, Perret B, Izopet J, Massip P: Evolution of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. Abstract 49: January 30–February 2, 2000 ID - ref36 ER - TY - JOUR AU - Estrada, V. AU - de Villar, N. G. P. AU - Larrad, M. T. M. AU - Lopez, A. G. AU - Fernandez, C. AU - Serrano-Rios, M. PY - 2002 DA - 2002// TI - Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy JO - Clin Infect Dis VL - 35 UR - https://doi.org/10.1086/340863 DO - 10.1086/340863 ID - Estrada2002 ER - TY - JOUR AU - Negredo, E. AU - Ribalta, J. AU - Paredes, R. AU - Ferré, R. AU - Sirera, G. AU - Ruiz, L. AU - Salazar, J. AU - Reiss, P. AU - Masana, L. AU - Clotet, B. PY - 2002 DA - 2002// TI - Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine JO - AIDS VL - 16 UR - https://doi.org/10.1097/00002030-200207050-00010 DO - 10.1097/00002030-200207050-00010 ID - Negredo2002 ER - TY - JOUR AU - Martínez, E. AU - Conget, I. AU - Lozano, L. AU - Casamitjana, R. AU - Gatell, J. M. PY - 1999 DA - 1999// TI - Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine JO - AIDS VL - 13 UR - https://doi.org/10.1097/00002030-199905070-00009 DO - 10.1097/00002030-199905070-00009 ID - Martínez1999 ER - TY - JOUR AU - Barreiro, P. AU - Soriano, V. AU - Blanco, F. AU - Casimiro, C. AU - de la Cruz, J. J. AU - Gonzalez-Lahoz, J. PY - 2000 DA - 2000// TI - Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy JO - AIDS VL - 14 UR - https://doi.org/10.1097/00002030-200005050-00006 DO - 10.1097/00002030-200005050-00006 ID - Barreiro2000 ER - TY - JOUR AU - Clotet, B. AU - van der Valk, M. AU - Negredo, E. AU - Reiss, P. PY - 2003 DA - 2003// TI - Impact of nevirapine on lipid metabolism JO - J Acquir Immune Defic Syndr VL - 34 UR - https://doi.org/10.1097/00126334-200309011-00012 DO - 10.1097/00126334-200309011-00012 ID - Clotet2003 ER - TY - JOUR AU - Fontas, E. AU - van Leth, F. AU - Sabin, C. A. AU - Friis-Møller, N. AU - Rickenbach, M. AU - Monforte, D. AU - Kirk, O. AU - Dupon, M. AU - Morfeldt, L. AU - Mateu, S. AU - Petoumenos, K. AU - El-Sadr, W. AU - de Wit, S. AU - Lundgren, J. D. AU - Pradier, C. AU - Reiss, P. PY - 2004 DA - 2004// TI - Lipid profiles in HIV-infected patients receiving combination antiretroviral drugs associated with different lipid profiles? JO - J Infect Dis VL - 189 UR - https://doi.org/10.1086/381783 DO - 10.1086/381783 ID - Fontas2004 ER - TY - JOUR AU - Bucher, H. C. AU - Kofler, A. AU - Nuesch, R. AU - Young, J. AU - Battegay, M. AU - Opravil, M. PY - 2003 DA - 2003// TI - Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients JO - AIDS VL - 17 UR - https://doi.org/10.1097/00002030-200311210-00007 DO - 10.1097/00002030-200311210-00007 ID - Bucher2003 ER - TY - STD TI - Gallant J, Staszewski AS, Pozniak A, Lu B, Miller MD, Coakley DF, Cheng A: Favorable lipid and mitochondrial (mt) DNA profile for tenofovir disoproxil fumarate (TDF) compared to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral therapy (ART) naïve patients: a 48-week interim analysis. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California. Abstract LB-2: September 27–30, 2002 ID - ref44 ER - TY - JOUR AU - Dreschler, H. AU - Powderly, W. G. PY - 2002 DA - 2002// TI - Switching effective antiretroviral therapy: a review JO - Clin Infect Dis VL - 35 UR - https://doi.org/10.1086/343050 DO - 10.1086/343050 ID - Dreschler2002 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/5/2/prepub UR - http://www.biomedcentral.com/1471-2334/5/2/prepub ID - ref46 ER -